Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hemispherx Enters Agreement With myTomorrows | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Hemispherx Enters Agreement With myTomorrows

Will focus on early access program for rintatolimod in Europe

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hemispherx Biopharma Inc. has formed an agreement with Impatients N.V., a Netherlands-based company doing business as myTomorrows, for the commencement and management of an early access program (EAP) in all of Europe and Turkey.

myTomorrows, as Hemispherx’ exclusive service provider in Europe and Turkey, will perform EAP activities in Europe and Turkey to include the supply of rintatolimod for the treatment of chronic fatigue syndrome (CFS) to patients with an unmet medical need.

“We are very pleased to be collaborating with myTomorrows to provide rintatolimod under these unique EAPs,” said Thomas Equels, executive vice chairman and chief financial officer, Hemispherx. “Not only will this collaboration create the possibility for physicians to use rintatolimod under certain circumstances, myTomorrows will collaborate with these physicians to capture data on patients treated and such data may add to our other efforts to gain full regulatory approval in Europe, Latin America, Australia, New Zealand as well as the U.S. and elsewhere.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics